Muraglitazar is a dual peroxisome proliferator-activated receptor agonist developed to manage type 2 diabetes by enhancing insulin sensitivity and lowering blood glucose levels. Analytical laboratories… Read more
Muraglitazar is a dual peroxisome proliferator-activated receptor agonist developed to manage type 2 diabetes by enhancing insulin sensitivity and lowering blood glucose levels. Analytical laboratories rely on high-quality reference standards of Muraglitazar to conduct rigorous quality control and method validation during pharmaceutical development. The accompanying range of impurities and metabolites, such as 4-hydroxy-3-(4-hydroxybenzyl)benzaldehyde and 2-(5-methyl-2-phenyloxazole-4-yl)ethanol, are essential for precise impurity profiling and the identification of degradation products in stability studies. Furthermore, stable isotope labelled compounds within this category serve as critical internal standards for accurate quantification in complex biological matrices, enabling robust bioanalytical method development. These research materials ensure adherence to regulatory guidelines throughout the manufacturing and testing lifecycle of this therapeutic agent.